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Psoriasis is one of the most prevalent T cell-mediated in-
flammatory disease in humans. It is also listed among the
most common autoimmune diseases (Davidson and Dia-
mond, 2001). It, however, shares with chronic inflammatory
diseases such as rheumatoid arthritis and Crohn’s disease
the absence of a known autoantigen. The pathogenesis of
psoriasis is thought to depend on the activation of lesional
and/or circulating T cells and their secreted products lead-
ing to keratinocyte hyperproliferation and angiogenesis with
marked ectasia of blood vessels (Lew et al, 2004; Nickoloff
and Nestle, 2004). There is convincing in vitro and in vivo
evidence in clinically relevant mouse models and humans
that tumor necrosis factor-a (TNF-a) is a master cytokine
relevant to the disease process (Chaudhari et al, 2001;
Boyman et al, 2004). Yet, the presence of TNF-a does not
fully account for the known T helper (Th) 1-dominated cyto-
kine milieu including the presence of ample amounts of in-
terferon-g (IFN-g) in lesional psoriatic skin. A key question in
psoriasis research relates therefore to factors orchestrating
the Th1-immune response in situ. Potential candidates in-
clude the interleukin (IL)-12 family members IL-12 and the
recently described cytokine IL-23. IL-12 p40 and p35 mRNA
as well as p70 protein has been detected in psoriasis
lesions (Yawalkar et al, 1998). Recent evidence, however
suggests that IL-23, rather than IL-12, might be a key cyto-
kine in psoriatic lesions based on the finding that p19 and
p40, but not p35mRNA are increased in psoriatic lesions
(Lee et al, 2004).
Both IL-12 and IL-23 are members of the IL-12 family of
cytokines sharing a common p40 subunit. p40 forms het-
erodimers with p35 in IL-12 and p19 in IL-23. IL-12 and
IL-23 bind to IL-12Rb1/IL-12Rb2 and IL-12Rb1/IL-23R, re-
spectively. Engagement of IL-23 with its receptor activates
a similar spectrum of Janus kinase (JAK)/signal transducer
and activator of transcription (STAT) molecules as IL-12 but
in contrast to IL-12, the most prominent STAT induced by
IL-23 are STAT3/STAT4 heterodimers rather than STAT4 ho-
modimers (Trinchieri et al, 2003). The physiological source
of IL-12 and IL-23 are similar. Many cell types express p19
or p35 mRNA, but the relatively restricted expression of p40
subunits limits potential IL-12- and IL-23-producing cells to
B cells, monocytes/macrophages and dendritic cells (DC).
The receptor complex for IL-12/IL-23 is expressed or
upregulated on T and NK cells, as well as on cells of the
myelomonocytic lineage including DC. The effects of IL-12
and IL-23 on the immune response are comparable but
distinct. Whereas IL-12 mainly stimulates IFN-g production
in naı¨ve Th cells, IL-23 preferentially stimulates IFN-g pro-
duction and proliferation of memory Th1 cells. On the basis
of the early known biology of these two cytokines it has
been suggested that IL-12 would play a role in the expan-
sion and stabilization of the Th1 response, and IL-23 would
sustain proliferation of memory T cells, thus maintaining a
Th1-committed memory response (Trinchieri et al, 2003).
Novel insight into the pathogenesis of psoriasis has
spurred the development of biologic therapies selectively
targeting key cytokines and receptor–ligand interactions
(Kupper, 2003; Lew et al, 2004; Nickoloff and Nestle, 2004).
The vision of a single cytokine as potential therapeutic tar-
get for the treatment of psoriasis has been validated with
the triumphant march of anti-TNF-a based therapies. Fusion
proteins or antibodies blocking the biological effects of
TNF-a have demonstrated potent anti-psoriatic activity in
phase I and II trials (Chaudhari et al, 2001; Leonardi et al,
2003). Based on these promising data the search is open for
other master cytokines with therapeutic potential in the
pathogenesis of psoriasis. One such candidate are mem-
bers of the IL-12 family of heterodimeric proteins sharing
the p40 chain.
In this issue, Kauffmann et al demonstrate in a phase I,
first in human, nonrandomized open label study that a single
intravenous infusion of a human neutralizing monoclonal
antibody to the human IL-12 family member p40 subunit
(anti-IL-12p40) is generally well tolerated and induces con-
centration-dependent improvements of psoriatic lesions.
The rationale for the study is that interruption of the IL-
12p40/IL-12Rb1 interaction will prevent the biological ac-
tivity of IL-12, IL-23 and potentially other IL-12 family mem-
bers with concomitant interference of the pathogenic Th1
environment in psoriasis. Eighteen patients with body sur-
face area ranging from 3% to 35% and at least two plaques
located on either the trunk or extremities were treated with a
single intravenous infusion. Doses ranged from 0.1 to 5.0
mg per kg. There were no serious adverse events related to
the study drug. The most commonly reported adverse
events included transient decreases in CD4þ and CD16/
56þ cells, headache, common cold symptoms and pain at
the biopsy site. Twelve of 18 subjects (67%) achieved at
least 75% improvement in psoriasis activity and severity
index (PASI) between 8 and 16 wk after study administra-
tion. Clinical improvements were concentration dependent.
Abbreviations: DC, dendritic cell; IFN-g, interferon-g; IL, interleukin;
Th1, T helper 1; STAT, signal transducer and activator of transcrip-
tion; TNF-a, tumor necrosis factor-a
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This phase I study suggests that anti-IL-12p40 repre-
sents an exciting new therapeutic target in plaque-type
psoriasis. It, however has to be mentioned that, as a result
of the early nature of clinical compound development, sev-
eral caveats remain and important questions are yet to be
answered. Long-term safety will be a primary concern in
future studies taking into account IL-12p40 knockout mice
data showing increased susceptibility to bacterial, parasitic
and especially mycobacterial infections (Lankford and
Frucht, 2003). Repeated infusions and their impact on safe-
ty and antibody induction need to be studied. Moreover,
solid clinical data on kinetics and duration of clinical re-
sponse are needed. It is too early to speculate about the
future place of anti-IL-12p40 in the arsenal of biologic
agents for psoriasis. Nonetheless, members of the IL-12
family of cytokines clearly have the potential to represent
the next master cytokine(s) in the pathogenesis and therapy
of psoriasis. One apparent difference compared with the
gold standard in anti-cytokine therapy, i.e., anti-TNF-a treat-
ment, is a potentially later onset of the therapeutic response
with anti-IL-12p40. This fact could be explained by the in-
terference of anti-IL-12p40 with effector molecules relevant
in later phases of the autoimmune response in psoriasis.
How can we integrate the findings of Kauffmann et al in
our current view of the pathogenesis of psoriasis?
The me´nage a trois between DC, T cells and keratin-
ocytes provides the basis for the unique molecular signa-
ture defining a typical psoriatic lesion. More specifically,
signals exchanged at the immunological synapse between
lesional myeloid DC and T cells as shown in Fig 1 are at the
center stage of the chronic inflammatory disease process.
The central role of TNF-a in shaping the psoriatic disease
process is well appreciated (Boyman et al, 2004); however,
signals driving the Th1-biased effector response need to be
defined in an in vivo setting in humans. The findings by
Kauffmann et al provide supportive evidence for a major role
of IL-12 family members such as IL-23 and IL-12 in the
pathogenesis of psoriasis, most likely by driving IFN-g pro-
duction by Th cells. The obvious cellular source of IL-12
family members are lesional DC activated by endogenous
(e.g., heat shock proteins) or exogenous (e.g., toll like re-
ceptor ligands) danger ligands, TNF-a or CD40L derived from
activated T cells. Future research needs to focus on a better
understanding of signals activating lesional DC and also has
to to investigate in more detail factors which drive the prom-
inent epidermal Tc1 response in psoriasis. Such work will
undoubtedly lead to novel molecular therapeutics for the
benefit of the numerous patients suffering from psoriasis.
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Figure 1
Integrating interleukin (IL)-12 family members IL-12 and IL-23 in
the pathogenesis of psoriasis. Dendritic cell (DC)–T cell interactions
are at the center stage of the psoriatic disease process. DC secrete IL-
12 family members such as IL-12 and IL-23 which share the common
IL-12p40 chain. Engagement of their respective receptors leads to
proliferation of lesional psoriatic Th1 memory cells as well as the se-
cretion of interferon (IFN)-g. This will turn on an IFN-dependent tran-
scriptional program typical for psoriasis and the downstream activation
of psoriasis-specific chemokines, inducible nitric oxide synthetase, and
IL-8. Tumor necrosis factor-a (TNF-a) is mainly produced by lesional
myelomonocytic cells and acts on DC as well as T cells. Open ques-
tions remain: the definition of ligands activating lesional DC in psoriasis
such as endogenous (e.g., heat shock proteins) or exogenous danger
ligands (pathogen derived products) as well as factors activating les-
ional Tc1 T cells.
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